ID

114

Descripción

ODM derived from http://clinicaltrials.gov/ct2/show/NCT00148213?term=NCT00148213&rank=1

Link

http://clinicaltrials.gov/ct2/show/NCT00148213?term=NCT00148213&rank=1

Palabras clave

Versiones (2)
  1. 24/11/11 24/11/11 -
  2. 9/7/15 9/7/15 - Martin Dugas
Subido en

24 de noviembre de 2011

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 3.0 Legacy
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility NCT00216879 Psoriasis

Inglés

Eligibility

1 formularios  
  1. StudyEvent: Eligibility
    1. Eligibility
Inclusion Criteria
Descripción

Inclusion Criteria

18 Years and older
Descripción

age

Tipo de datos

boolean

Scalp psoriasis amenable to topical treatment with a maximum of 100 g of study medication per week
Descripción

Scalp psoriasis

Tipo de datos

boolean

Clinical signs of psoriasis vulgaris on trunk and/or limbs, or earlier diagnosed with psoriasis vulgaris on trunk and/or limbs
Descripción

Psoriasis vulgaris

Tipo de datos

boolean

Extent of scalp psoriasis involving more than 10% of the total scalp area
Descripción

Extension

Tipo de datos

boolean

Disease severity on the scalp graded as Moderate, Severe or Very Severe according to the Investigator's Global Assessment of disease severity
Descripción

Disease severity

Tipo de datos

boolean

Exclusion Criteria
Descripción

Exclusion Criteria

PUVA or Grenz ray therapy anywhere on the patient within 28 days prior to randomisation
Descripción

PUVA or Grenz ray Radiation therapy

Tipo de datos

boolean

UVB therapy anywhere on the patient within 14 days prior to randomisation
Descripción

UVB therapy

Tipo de datos

boolean

Systemic use of biological treatments, whether marketed or not, directed against or with a potential effect on, scalp psoriasis (e.g., alefacept, efalizumab, etanercept, infliximab) within 6 months prior to randomisaiton
Descripción

Biologicals

Tipo de datos

boolean

Systemic treatments with a potential effect on scalp psoriasis vulgaris (e.g., corticosteroids, retinoids, immunosuppressants) within 28 days prior to randomisation
Descripción

Systemic treatment with effect on scalp psoriasis

Tipo de datos

boolean

Any topical treatment for scalp psoriasis or any other skin disease on the scalp (excluding medicated shampoos, emollients and hair conditioners) within 14 days prior to randomisaiton
Descripción

topical treatment for scalp

Tipo de datos

boolean

Topical treatment for other skin disorders with very potent WHO group IV corticosteroids within 14 days prior to randomisation
Descripción

Topical treatment with very potent WHO group IV corticosteroids

Tipo de datos

boolean

Planned initiation of, or changes in dose of concomitant medication that could affect scalp psoriasis (e.g., beta blockers, antimalarial drugs, lithium) during the study
Descripción

Planned initiation of, or changes in dose of concomitant medication that could affect scalp psoriasis

Tipo de datos

boolean

Current diagnosis of guttate, pustular, exfoliative or erythrodermic psoriasis
Descripción

guttate, pustular, exfoliative or erythrodermic psoriasis

Tipo de datos

boolean

Patients with any of the following conditions present on the scalp area: viral lesions, fungal and bacterial skin infections, parasitic infections and atrophic skin
Descripción

viral lesions, fungal and bacterial skin infections, parasitic infections and atrophic skin on the scalp

Tipo de datos

boolean

Known or suspected severe renal insufficiency or severe hepatic disorders
Descripción

renal insufficiency or severe hepatic disorders

Tipo de datos

boolean

Patiens with history/signs/symptoms suggestive of an abnormality of calcium homeostasis associated with clinically significant hypercalcaemia
Descripción

clinically significant hypercalcaemia

Tipo de datos

boolean

Trial subjects should be using an adequate method of contraception
Descripción

contraception

Tipo de datos

boolean

Medical Concepts
Descripción

Medical Concepts

Age
Descripción

Age

Tipo de datos

string

Alias
UMLS CUI
C0001779
SNOMED CT 2010_0731
102518004
Diagnosis
Descripción

Diagnosis

Tipo de datos

string

Alias
UMLS CUI
C0011900
SNOMED CT 2010_0731
439401001
LOINC Version 232
MTHU008876
Psoriasis
Descripción

Psoriasis

Tipo de datos

string

Alias
UMLS CUI
C0033860
SNOMED CT 2010_0731
9014002
MedDRA 13.1
10037153
ICD-10-CM Version 2010
L40
Scalp psoriasis
Descripción

Scalp psoriasis

Tipo de datos

string

Alias
UMLS CUI
C0406326
SNOMED CT 2010_0731
238608008
MedDRA 13.1
10037157
Psoriasis vulgaris
Descripción

Psoriasis vulgaris

Tipo de datos

string

Alias
UMLS CUI
C0263361
MedDRA 13.1
10050576
ICD-10-CM Version 2010
L40.0
Extension
Descripción

Extension

Tipo de datos

string

Alias
UMLS CUI
C0231448
SNOMED CT 2010_0731
255536004
LOINC Version 232
MTHU010348
Disease severity
Descripción

Severity Code

Tipo de datos

string

Alias
UMLS CUI
CL425496
treatment
Descripción

Therapy

Tipo de datos

string

Alias
UMLS CUI
C0039798
radiation
Descripción

Radiation

Tipo de datos

string

Alias
UMLS CUI
C0851346
SNOMED CT 2010_0731
82107009
LOINC Version 232
MTHU026213
PUVA
Descripción

PUVA

Tipo de datos

string

Alias
UMLS CUI
C0853073
MedDRA 13.1
10037580
Rays, Grenz
Descripción

Grenz ray

Tipo de datos

string

Alias
UMLS CUI
C0018233
SNOMED CT 2010_0731
52250000
Ultraviolet B Radiation
Descripción

UVB

Tipo de datos

string

Alias
UMLS CUI
C0564461
SNOMED CT 2010_0731
286632006
Medication
Descripción

Pharmaceutical Preparations

Tipo de datos

string

Alias
UMLS CUI
C0013227
Biological agent
Descripción

Biological Products

Tipo de datos

string

Alias
UMLS CUI
C0005522
SNOMED CT 2010_0731
418980009
Skin care: topical treatments
Descripción

topical treatment

Tipo de datos

string

Alias
UMLS CUI
C0150349
SNOMED CT 2010_0731
386439008
Therapeutic Corticosteroid
Descripción

corticosteroids

Tipo de datos

string

Alias
UMLS CUI
C0001617
SNOMED CT 2010_0731
79440004
Psoriasis guttata
Descripción

guttate psoriasis

Tipo de datos

string

Alias
UMLS CUI
C0343052
SNOMED CT 2010_0731
37042000
ICD-10-CM Version 2010
L40.4
pustular psoriasis
Descripción

pustular psoriasis

Tipo de datos

string

Alias
UMLS CUI
C0152081
SNOMED CT 2010_0731
200973000
MedDRA 13.1
10037159
exfoliative psoriasis
Descripción

erythrodermic psoriasis

Tipo de datos

string

Alias
UMLS CUI
C0748052
SNOMED CT 2010_0731
200977004
MedDRA 13.1
10015278
Infection
Descripción

Infection

Tipo de datos

string

Alias
UMLS CUI
C0021311
SNOMED CT 2010_0731
257551009
MedDRA 13.1
10021789
Atrophic condition of skin
Descripción

atrophic skin

Tipo de datos

string

Alias
UMLS CUI
C0151514
SNOMED CT 2010_0731
400190005
MedDRA 13.1
10040799
ICD-10-CM Version 2010
L90.9
CTCAE Version 4.03
E13714
Renal Insufficiency
Descripción

renal insufficiency

Tipo de datos

string

Alias
UMLS CUI
C1565489
MedDRA 13.1
10022467
Hepatic disorders (SMQ)
Descripción

hepatic disorders

Tipo de datos

string

Alias
UMLS CUI
C1869009
MedDRA 13.1
20000005
Hypercalcemia
Descripción

hypercalcaemia

Tipo de datos

string

Alias
UMLS CUI
C0020437
SNOMED CT 2010_0731
66931009
MedDRA 13.1
10020583
ICD-10-CM Version 2010
E83.52
ICD-9-CM Version 2011
275.42
CTCAE Version 4.03
E12270
Contraception
Descripción

Contraception

Tipo de datos

string

Alias
UMLS CUI
C0700589
SNOMED CT 2010_0731
146680009
MedDRA 13.1
10010808
Volver a la parte superior de la página

Similar models

Eligibility

1 formularios
  1. StudyEvent: Eligibility
    1. Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
Inclusion Criteria
age
Item
18 Years and older
boolean
Scalp psoriasis
Item
Scalp psoriasis amenable to topical treatment with a maximum of 100 g of study medication per week
boolean
Psoriasis vulgaris
Item
Clinical signs of psoriasis vulgaris on trunk and/or limbs, or earlier diagnosed with psoriasis vulgaris on trunk and/or limbs
boolean
Extension
Item
Extent of scalp psoriasis involving more than 10% of the total scalp area
boolean
Disease severity
Item
Disease severity on the scalp graded as Moderate, Severe or Very Severe according to the Investigator's Global Assessment of disease severity
boolean
Item Group
Exclusion Criteria
PUVA or Grenz ray Radiation therapy
Item
PUVA or Grenz ray therapy anywhere on the patient within 28 days prior to randomisation
boolean
UVB therapy
Item
UVB therapy anywhere on the patient within 14 days prior to randomisation
boolean
Biologicals
Item
Systemic use of biological treatments, whether marketed or not, directed against or with a potential effect on, scalp psoriasis (e.g., alefacept, efalizumab, etanercept, infliximab) within 6 months prior to randomisaiton
boolean
Systemic treatment with effect on scalp psoriasis
Item
Systemic treatments with a potential effect on scalp psoriasis vulgaris (e.g., corticosteroids, retinoids, immunosuppressants) within 28 days prior to randomisation
boolean
topical treatment for scalp
Item
Any topical treatment for scalp psoriasis or any other skin disease on the scalp (excluding medicated shampoos, emollients and hair conditioners) within 14 days prior to randomisaiton
boolean
Topical treatment with very potent WHO group IV corticosteroids
Item
Topical treatment for other skin disorders with very potent WHO group IV corticosteroids within 14 days prior to randomisation
boolean
Planned initiation of, or changes in dose of concomitant medication that could affect scalp psoriasis
Item
Planned initiation of, or changes in dose of concomitant medication that could affect scalp psoriasis (e.g., beta blockers, antimalarial drugs, lithium) during the study
boolean
guttate, pustular, exfoliative or erythrodermic psoriasis
Item
Current diagnosis of guttate, pustular, exfoliative or erythrodermic psoriasis
boolean
viral lesions, fungal and bacterial skin infections, parasitic infections and atrophic skin on the scalp
Item
Patients with any of the following conditions present on the scalp area: viral lesions, fungal and bacterial skin infections, parasitic infections and atrophic skin
boolean
renal insufficiency or severe hepatic disorders
Item
Known or suspected severe renal insufficiency or severe hepatic disorders
boolean
clinically significant hypercalcaemia
Item
Patiens with history/signs/symptoms suggestive of an abnormality of calcium homeostasis associated with clinically significant hypercalcaemia
boolean
contraception
Item
Trial subjects should be using an adequate method of contraception
boolean
Item Group
Medical Concepts
Age
Item
Age
string
C0001779 (UMLS CUI)
102518004 (SNOMED CT 2010_0731)
Diagnosis
Item
Diagnosis
string
C0011900 (UMLS CUI)
439401001 (SNOMED CT 2010_0731)
MTHU008876 (LOINC Version 232)
Psoriasis
Item
Psoriasis
string
C0033860 (UMLS CUI)
9014002 (SNOMED CT 2010_0731)
10037153 (MedDRA 13.1)
L40 (ICD-10-CM Version 2010)
Scalp psoriasis
Item
Scalp psoriasis
string
C0406326 (UMLS CUI)
238608008 (SNOMED CT 2010_0731)
10037157 (MedDRA 13.1)
Psoriasis vulgaris
Item
Psoriasis vulgaris
string
C0263361 (UMLS CUI)
10050576 (MedDRA 13.1)
L40.0 (ICD-10-CM Version 2010)
Extension
Item
Extension
string
C0231448 (UMLS CUI)
255536004 (SNOMED CT 2010_0731)
MTHU010348 (LOINC Version 232)
Severity Code
Item
Disease severity
string
CL425496 (UMLS CUI)
Therapy
Item
treatment
string
C0039798 (UMLS CUI)
Radiation
Item
radiation
string
C0851346 (UMLS CUI)
82107009 (SNOMED CT 2010_0731)
MTHU026213 (LOINC Version 232)
PUVA
Item
PUVA
string
C0853073 (UMLS CUI)
10037580 (MedDRA 13.1)
Grenz ray
Item
Rays, Grenz
string
C0018233 (UMLS CUI)
52250000 (SNOMED CT 2010_0731)
UVB
Item
Ultraviolet B Radiation
string
C0564461 (UMLS CUI)
286632006 (SNOMED CT 2010_0731)
Pharmaceutical Preparations
Item
Medication
string
C0013227 (UMLS CUI)
Biological Products
Item
Biological agent
string
C0005522 (UMLS CUI)
418980009 (SNOMED CT 2010_0731)
topical treatment
Item
Skin care: topical treatments
string
C0150349 (UMLS CUI)
386439008 (SNOMED CT 2010_0731)
corticosteroids
Item
Therapeutic Corticosteroid
string
C0001617 (UMLS CUI)
79440004 (SNOMED CT 2010_0731)
guttate psoriasis
Item
Psoriasis guttata
string
C0343052 (UMLS CUI)
37042000 (SNOMED CT 2010_0731)
L40.4 (ICD-10-CM Version 2010)
pustular psoriasis
Item
pustular psoriasis
string
C0152081 (UMLS CUI)
200973000 (SNOMED CT 2010_0731)
10037159 (MedDRA 13.1)
erythrodermic psoriasis
Item
exfoliative psoriasis
string
C0748052 (UMLS CUI)
200977004 (SNOMED CT 2010_0731)
10015278 (MedDRA 13.1)
Infection
Item
Infection
string
C0021311 (UMLS CUI)
257551009 (SNOMED CT 2010_0731)
10021789 (MedDRA 13.1)
atrophic skin
Item
Atrophic condition of skin
string
C0151514 (UMLS CUI)
400190005 (SNOMED CT 2010_0731)
10040799 (MedDRA 13.1)
L90.9 (ICD-10-CM Version 2010)
E13714 (CTCAE Version 4.03)
renal insufficiency
Item
Renal Insufficiency
string
C1565489 (UMLS CUI)
10022467 (MedDRA 13.1)
hepatic disorders
Item
Hepatic disorders (SMQ)
string
C1869009 (UMLS CUI)
20000005 (MedDRA 13.1)
hypercalcaemia
Item
Hypercalcemia
string
C0020437 (UMLS CUI)
66931009 (SNOMED CT 2010_0731)
10020583 (MedDRA 13.1)
E83.52 (ICD-10-CM Version 2010)
275.42 (ICD-9-CM Version 2011)
E12270 (CTCAE Version 4.03)
Contraception
Item
Contraception
string
C0700589 (UMLS CUI)
146680009 (SNOMED CT 2010_0731)
10010808 (MedDRA 13.1)
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial